[4-[2-amino-10-(6-fluoroquinolin-3-yl)-4-methyl-1,6,8,12-tetrazatricyclo[7.3.0.03,7]dodeca-2,4,7,9,11-pentaen-6-yl]piperidin-1-yl]-(1H-1,2,4-triazol-5-yl)methanone | 1372398-99-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [4-[2-amino-10-(6-fluoroquinolin-3-yl)-4-methyl-1,6,8,12-tetrazatricyclo[7.3.0.03,7]dodeca-2,4,7,9,11-pentaen-6-yl]piperidin-1-yl]-(1H-1,2,4-triazol-5-yl)methanone
• CAS: 1372398-99-6
• 化学式: C₂₆H₂₃FN₁₀O
• 分子量: 510.533
• InChiKey: NQCWOXXWOPPPRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  38
• 可旋转键数：
  3
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• [EN] FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN<br/>[FR] COMPOSÉS TRICYCLIQUES ACCOLÉS INHIBITEURS DE LA CIBLE MAMMIFÈRE DE LA RAPAMYCINE
  申请人：SCHERING CORP

  公开号：WO2012047570A1

  公开（公告）日：2012-04-12

  This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.

  这项发明涉及新型融合三环化合物，它们是哺乳动物雷帕霉素靶蛋白（mTOR）激酶的抑制剂，也被称为FRAP、RAFT、RAPT或SEP，并且在治疗细胞增殖性疾病（例如癌症和其他增殖性疾病）中非常有用。
• FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN
  申请人：Meng Zhaoyang

  公开号：US20130281474A1

  公开（公告）日：2013-10-24

  This invention relates to novel fused tricyclic compounds that are inhibitors of mammalian Target of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP, and are useful in the treatment of cellular proliferative diseases, for example cancer and other proliferative disorders.

  本发明涉及一种新颖的融合三环化合物，它们是哺乳动物雷帕霉素靶向蛋白(mTOR)激酶的抑制剂，也被称为FRAP、RAFT、RAPT或SEP，并且在治疗细胞增殖性疾病，例如癌症和其他增殖性疾病方面有用。
• US8927562B2
  申请人：——

  公开号：US8927562B2

  公开（公告）日：2015-01-06